Skip to main content
Erschienen in: Surgery Today 7/2021

20.01.2021 | Short Communication

The prognostic impact of peritoneal washing cytology for otherwise resectable extrahepatic cholangiocarcinoma patients

verfasst von: Tatsuaki Sumiyoshi, Kenichiro Uemura, Naru Kondo, Kenjiro Okada, Shingo Seo, Hiroyuki Otsuka, Masahiro Serikawa, Yasutaka Ishii, Norimasa Kuraoka, Takuya Sakoda, Kenta Baba, Takumi Harada, Yoshiaki Murakami, Shinya Takahashi

Erschienen in: Surgery Today | Ausgabe 7/2021

Einloggen, um Zugang zu erhalten

Abstract

The clinical importance of peritoneal washing cytology (PWC) for cholangiocarcinoma patients remains unclear. The clinical data of 137 extrahepatic cholangiocarcinoma patients who received PWC and curative surgery were retrospectively analyzed. Among the 137 patients analyzed, five (3.6%) had positive PWC, and 132 (96.4%) had negative PWC. The median survival time in patients with negative PWC was 6.45 years, and the overall 1-, 2-, and 5-year survival rates were 86.5%, 75.3%, and 51.6%, respectively. The median survival time in patients with positive PWC was 2.56 years, and the overall 1-, 2-, and 5-year survival rates were 60.0%, 60.0%, and 40.0%, respectively. A multivariate analysis revealed that positive lymph node metastasis (P < 0.001), positive perineural invasion (P = 0.014) and no use of adjuvant chemotherapy (P < 0.001), but not positive PWC were independently associated with a worse overall survival. In conclusion, surgery and subsequent chemotherapy might be a therapeutic option for cholangiocarcinoma patients with positive PWC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BSJ, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234:507–17.CrossRef Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BSJ, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234:507–17.CrossRef
2.
Zurück zum Zitat de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999;341:1368–78.CrossRef de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999;341:1368–78.CrossRef
3.
Zurück zum Zitat Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma—evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15:95–111.CrossRef Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma—evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15:95–111.CrossRef
4.
Zurück zum Zitat Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37:806–13.CrossRef Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37:806–13.CrossRef
5.
Zurück zum Zitat Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut. 2001;48:816–20.CrossRef Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut. 2001;48:816–20.CrossRef
6.
Zurück zum Zitat Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Nakagawa N, et al. Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies. J Gastrointest Surg. 2013;17:1429–39.CrossRef Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Nakagawa N, et al. Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies. J Gastrointest Surg. 2013;17:1429–39.CrossRef
7.
Zurück zum Zitat Nagahashi M, Shirai Y, Wakai T, Sakata J, Ajioka Y, Nomura T, et al. Depth of invasion determines the postresectional prognosis for patients with T1 extrahepatic cholangiocarcinoma. Cancer. 2010;116:400–5.CrossRef Nagahashi M, Shirai Y, Wakai T, Sakata J, Ajioka Y, Nomura T, et al. Depth of invasion determines the postresectional prognosis for patients with T1 extrahepatic cholangiocarcinoma. Cancer. 2010;116:400–5.CrossRef
8.
Zurück zum Zitat Blom D, Schwartz SI. Surgical treatment and outcomes in carcinoma of the extrahepatic bile ducts: the University of Rochester experience. Arch Surg. 2001;136:209–15.CrossRef Blom D, Schwartz SI. Surgical treatment and outcomes in carcinoma of the extrahepatic bile ducts: the University of Rochester experience. Arch Surg. 2001;136:209–15.CrossRef
9.
Zurück zum Zitat Smith AM, Liaskos C, Verbeke CS. Impact of intrapancreatic or extrapancreatic bile duct involvement on survival following pancreatoduodenectomy for common bile duct cancer. Br J Surg. 2014;101:89–99.PubMed Smith AM, Liaskos C, Verbeke CS. Impact of intrapancreatic or extrapancreatic bile duct involvement on survival following pancreatoduodenectomy for common bile duct cancer. Br J Surg. 2014;101:89–99.PubMed
10.
Zurück zum Zitat Jang JY, Kim SW, Park DJ, Ahn YJ, Yoon YS, Choi MG, et al. Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg. 2005;241:77–84.CrossRef Jang JY, Kim SW, Park DJ, Ahn YJ, Yoon YS, Choi MG, et al. Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg. 2005;241:77–84.CrossRef
11.
Zurück zum Zitat Sakamoto Y, Kosuge T, Shimada K, Sano T, Ojima H, Yamamoto J, et al. Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery. 2005;137:396–402.CrossRef Sakamoto Y, Kosuge T, Shimada K, Sano T, Ojima H, Yamamoto J, et al. Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery. 2005;137:396–402.CrossRef
12.
Zurück zum Zitat Endo S, Ikenaga M, Ohta K, Ueda M, Tsuda Y, Kato R, et al. Prognostic factors for cytology-positive gastric cancer. Surg Today. 2019;49:56–64.CrossRef Endo S, Ikenaga M, Ohta K, Ueda M, Tsuda Y, Kato R, et al. Prognostic factors for cytology-positive gastric cancer. Surg Today. 2019;49:56–64.CrossRef
13.
Zurück zum Zitat Amin M, Edge S, Greene F. The AJCC TNM cancer staging manual. 8th ed. New York: Springer; 2017.CrossRef Amin M, Edge S, Greene F. The AJCC TNM cancer staging manual. 8th ed. New York: Springer; 2017.CrossRef
14.
Zurück zum Zitat Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1–5.CrossRef Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1–5.CrossRef
15.
Zurück zum Zitat Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th ed. Oxford: Wiley-Blackwell; 2017. Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th ed. Oxford: Wiley-Blackwell; 2017.
16.
Zurück zum Zitat Ferrone CR, Haas B, Tang L, Coit DG, Fong Y, Brennan MF, et al. The influence of positive peritoneal cytology on survival in patients with pancreatic adenocarcinoma. J Gastrrointest Surg. 2006;10:1347–53.CrossRef Ferrone CR, Haas B, Tang L, Coit DG, Fong Y, Brennan MF, et al. The influence of positive peritoneal cytology on survival in patients with pancreatic adenocarcinoma. J Gastrrointest Surg. 2006;10:1347–53.CrossRef
17.
Zurück zum Zitat Tsuchida H, Fujii T, Mizuma M, Satoi S, Igarashi H, Eguchi H, Committee of Clinical Research, Japan Pancreas Society, et al. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nationwide, cancer registry-based study from the Japan Pancreas Society. Surgery. 2019;166:997–1003.CrossRef Tsuchida H, Fujii T, Mizuma M, Satoi S, Igarashi H, Eguchi H, Committee of Clinical Research, Japan Pancreas Society, et al. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nationwide, cancer registry-based study from the Japan Pancreas Society. Surgery. 2019;166:997–1003.CrossRef
18.
Zurück zum Zitat Japan Pancreas Society. Classification of pancreatic carcinoma. General rules for the study of pancreatic cancer. 4th ed. Tokyo: Kanerhara & Co; 2017. Japan Pancreas Society. Classification of pancreatic carcinoma. General rules for the study of pancreatic cancer. 4th ed. Tokyo: Kanerhara & Co; 2017.
19.
Zurück zum Zitat Martin RC 2nd, Fong Y, DeMatteo RP, et al. Peritoneal washings are not predictive of occult peritoneal disease in patients with hilar cholangiocarcinoma. J Am Coll Surg. 2001;193:620–5.CrossRef Martin RC 2nd, Fong Y, DeMatteo RP, et al. Peritoneal washings are not predictive of occult peritoneal disease in patients with hilar cholangiocarcinoma. J Am Coll Surg. 2001;193:620–5.CrossRef
20.
Zurück zum Zitat Kawakami H, Kuwatani M, Onodera M, Haba S, Eto K, Ehira N, et al. Endoscopic nasobiliary drainage is the most suitable preoperative biliary drainage method in the management of patients with hilar cholangiocarcinoma. J Gastroenterol. 2011;46:242–8.CrossRef Kawakami H, Kuwatani M, Onodera M, Haba S, Eto K, Ehira N, et al. Endoscopic nasobiliary drainage is the most suitable preoperative biliary drainage method in the management of patients with hilar cholangiocarcinoma. J Gastroenterol. 2011;46:242–8.CrossRef
21.
Zurück zum Zitat Hwang S, Jung SW, Namgoong JM, Yoon SY, Park GC, Jung DH, et al. Solitary percutaneous transhepatic biliary drainage tract metastasis after curative resection of perihilar cholangiocarcinoma: report of a case. Korean J Hepatobiliary Pancreat Surg. 2011;15:179–83.CrossRef Hwang S, Jung SW, Namgoong JM, Yoon SY, Park GC, Jung DH, et al. Solitary percutaneous transhepatic biliary drainage tract metastasis after curative resection of perihilar cholangiocarcinoma: report of a case. Korean J Hepatobiliary Pancreat Surg. 2011;15:179–83.CrossRef
22.
Zurück zum Zitat Kim KM, Park JW, Lee JK, Lee KH, Lee KT, Shim SG. A comparison of preoperative biliary drainage methods for perihilar cholangiocarcinoma: endoscopic versus percutaneous transhepatic biliary drainage. Gut Liver. 2015;9:791–9.CrossRef Kim KM, Park JW, Lee JK, Lee KH, Lee KT, Shim SG. A comparison of preoperative biliary drainage methods for perihilar cholangiocarcinoma: endoscopic versus percutaneous transhepatic biliary drainage. Gut Liver. 2015;9:791–9.CrossRef
23.
Zurück zum Zitat Uemura K, Murakami Y, Satoi S, Sho M, Motoi F, Kawai M, et al. Impact of preoperative biliary drainage on long-term survival in resected pancreatic ductal adenocarcinoma: a multicenter observational study. Ann Surg Oncol. 2015;22(S3):1238–46.CrossRef Uemura K, Murakami Y, Satoi S, Sho M, Motoi F, Kawai M, et al. Impact of preoperative biliary drainage on long-term survival in resected pancreatic ductal adenocarcinoma: a multicenter observational study. Ann Surg Oncol. 2015;22(S3):1238–46.CrossRef
24.
Zurück zum Zitat Komaya K, Ebata T, Fukami Y, Sakamoto E, Miyake H, Takara D, et al. Percutaneous biliary drainage is oncologically inferior to endoscopic drainage: a propensity score matching analysis in resectable distal cholangiocarcinoma. J Gastroenterol. 2016;51:608–19.CrossRef Komaya K, Ebata T, Fukami Y, Sakamoto E, Miyake H, Takara D, et al. Percutaneous biliary drainage is oncologically inferior to endoscopic drainage: a propensity score matching analysis in resectable distal cholangiocarcinoma. J Gastroenterol. 2016;51:608–19.CrossRef
25.
Zurück zum Zitat Higuchi R, Yazawa T, Uemura S, Izumo W, Chaudhary RJ, Furukawa T, et al. ENBD is associated with decreased tumor dissemination compared to PTBD in perihilar cholangiocarcinoma. J Gastrointest Surg. 2017;21:1506–14.CrossRef Higuchi R, Yazawa T, Uemura S, Izumo W, Chaudhary RJ, Furukawa T, et al. ENBD is associated with decreased tumor dissemination compared to PTBD in perihilar cholangiocarcinoma. J Gastrointest Surg. 2017;21:1506–14.CrossRef
26.
Zurück zum Zitat Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.CrossRef Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.CrossRef
27.
Zurück zum Zitat Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H, et al. Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg. 2009;250:950–6.CrossRef Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H, et al. Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg. 2009;250:950–6.CrossRef
28.
Zurück zum Zitat Ebata T, Hirano S, Konishi M, Uesaka K, Tsuchiya Y, Ohtsuka M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105:192–202.CrossRef Ebata T, Hirano S, Konishi M, Uesaka K, Tsuchiya Y, Ohtsuka M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105:192–202.CrossRef
29.
Zurück zum Zitat Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20:663–73.CrossRef Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20:663–73.CrossRef
Metadaten
Titel
The prognostic impact of peritoneal washing cytology for otherwise resectable extrahepatic cholangiocarcinoma patients
verfasst von
Tatsuaki Sumiyoshi
Kenichiro Uemura
Naru Kondo
Kenjiro Okada
Shingo Seo
Hiroyuki Otsuka
Masahiro Serikawa
Yasutaka Ishii
Norimasa Kuraoka
Takuya Sakoda
Kenta Baba
Takumi Harada
Yoshiaki Murakami
Shinya Takahashi
Publikationsdatum
20.01.2021
Verlag
Springer Singapore
Erschienen in
Surgery Today / Ausgabe 7/2021
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-020-02208-y

Weitere Artikel der Ausgabe 7/2021

Surgery Today 7/2021 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.